Delivery Order SPE2DB22D2007-SPE2DB25FJ3RT
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) at a ceiling value of $1,665.22. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Vyvanse 10 mg capsules in quantities of 100 units. This is a firm fixed price delivery order with a ceiling value of $1,933.29 and an ultimate completion date of August 21, 2025. The contract involves no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $2,354.62. This is a non-set-aside competitive award with an ultimate completion date of August 25, 2025, and performance will be executed from the awardee's Conshohocken, Pennsylvania location. The delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 30 mg capsules (100 count) under a firm fixed-price contract with a ceiling value of $1,918.73. The award, issued on July 31, 2025, with an ultimate completion date of August 1, 2025, represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $2,079.25. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025. The award represents a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Vyvanse 20 mg capsules (100 count) with a ceiling value of $4,284.71. This is a firm fixed price delivery order with an ultimate completion date of July 28, 2025. The award was competitively procured with no set-aside designation, and performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) with a ceiling value of $2,090.42. The order, classified as a child contract under a firm fixed-price arrangement with no set-aside designation, is scheduled for completion by July 23, 2025, with performance at the contractor's Conshohocken, Pennsylvania facility. This delivery order falls under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 15, 2025, for the supply of Vyvanse 30 mg capsules (quantity 100) with a contract value of $1,163.08. This is a firm fixed price delivery order with an ultimate completion date of July 16, 2025, and represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Vyvanse 20 mg capsules (100-count units) under a firm fixed-price contract valued at $6,292.03. The order, which is not set-aside for any disadvantaged business category, is scheduled for completion by August 13, 2025, and will be performed at the vendor's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) under a firm fixed-price contract valued at $2,196.14. This is a non-set-aside award, indicating competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 30, 2025. This delivery order is issued against...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3RTDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $5,051.16. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set for ultimate completion by August 6, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), a comprehensive pharmaceutical prime vendor contract valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp is one of the nation's largest pharmaceutical distributors and serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and other government entities. As a prime contractor under the DLA's pharmaceutical supply vehicle, the company supplies an extensive portfolio of medications and medical supplies across multiple therapeutic domains. The current delivery order for Vyvanse, a controlled pharmaceutical used primarily for attention deficit hyperactivity disorder treatment, represents a routine supply fulfillment supporting military healthcare operations and readiness.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.1k | 8/5/25 |